Clinical Trial Update: Extended-Release RANCAD in the Patients With Stable Angina Pectoris [Phase 3]

View source ↗

Summary

Phase 3 trial of an extended-release formulation of RANCAD in patients with stable angina pectoris has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Stable Angina Pectoris

Drugs mentioned

• RANCAD Extended-Release (RANCAD)

Snippet

Sponsor: TSH Biopharm Corporation Limited | Conditions: Stable Angina Pectoris | Phase 3 | Status: COMPLETED